Umama Ali
YOU?
Author Swipe
View article: Figure S1 from Treatment of Prostate Cancer with CD46-targeted <sup>225</sup>Ac Alpha Particle Radioimmunotherapy
Figure S1 from Treatment of Prostate Cancer with CD46-targeted <sup>225</sup>Ac Alpha Particle Radioimmunotherapy Open
Figure S1: Immunohistochemical staining for PSMA expression on tissue section from patient-derived xenografts. Scale bar = 200 µm
View article: Figure S4 from Treatment of Prostate Cancer with CD46-targeted <sup>225</sup>Ac Alpha Particle Radioimmunotherapy
Figure S4 from Treatment of Prostate Cancer with CD46-targeted <sup>225</sup>Ac Alpha Particle Radioimmunotherapy Open
Figure S4: Gamma energy spectra of the tumor, blood, kidneys, and bone showing the intensities of the 213Bi and 221Fr peaks. As compared to the equilibrium gamma energy spectra of [225Ac]DOTA-YS5, increased intensity of the 213Bi was obser…
View article: Figure S5 from Treatment of Prostate Cancer with CD46-targeted <sup>225</sup>Ac Alpha Particle Radioimmunotherapy
Figure S5 from Treatment of Prostate Cancer with CD46-targeted <sup>225</sup>Ac Alpha Particle Radioimmunotherapy Open
Figure S5: Estimated equivalent doses (in Sv) in organs and tumor indicating the highest dose (37 Sv) was delivered to tumor tissue.
View article: Figure S3 from Treatment of Prostate Cancer with CD46-targeted <sup>225</sup>Ac Alpha Particle Radioimmunotherapy
Figure S3 from Treatment of Prostate Cancer with CD46-targeted <sup>225</sup>Ac Alpha Particle Radioimmunotherapy Open
Figure S3: Binding of [225Ac]DOTA-YS5 to 22Rv1 with or without cold antibody blocking. Blocking with cold YS5 results in a reduction of binding from 19.25±0.70% to 4.46±0.17% (n=3).
View article: Figure S2 from Treatment of Prostate Cancer with CD46-targeted <sup>225</sup>Ac Alpha Particle Radioimmunotherapy
Figure S2 from Treatment of Prostate Cancer with CD46-targeted <sup>225</sup>Ac Alpha Particle Radioimmunotherapy Open
Figure S2: A, MALDI-TOF Mass spectroscopy results show 8.7 equivalents of DOTA molecules on the YS5 antibody. The number of DOTA were calculated by dividing the difference of m/z between YS5 and DOTA-YS5 by the molecular weight of DOTA. B,…
View article: Figure S7 from Treatment of Prostate Cancer with CD46-targeted <sup>225</sup>Ac Alpha Particle Radioimmunotherapy
Figure S7 from Treatment of Prostate Cancer with CD46-targeted <sup>225</sup>Ac Alpha Particle Radioimmunotherapy Open
Figure S7: Analysis of CD46 expression in correlation with of the [225Ac]DOTA-YS5 uptake and DNA damage. Digital autographs, H &E staining, and immunofluorescence (Rabbit Isotype control+DAPI, CD46 & phospho-γ-H2Ax) of the tumor tissues in…
View article: Figure S8 from Treatment of Prostate Cancer with CD46-targeted <sup>225</sup>Ac Alpha Particle Radioimmunotherapy
Figure S8 from Treatment of Prostate Cancer with CD46-targeted <sup>225</sup>Ac Alpha Particle Radioimmunotherapy Open
Figure S8: Acute toxicity study of the [225Ac]DOTA-YS5 in nude mice (n=5). A The body weights of mice injected with [225Ac]DOTA-YS5 showed no significant change in treatment groups over the 15 days study period. B&C: Liver and kidney funct…
View article: Figure S10 from Treatment of Prostate Cancer with CD46-targeted <sup>225</sup>Ac Alpha Particle Radioimmunotherapy
Figure S10 from Treatment of Prostate Cancer with CD46-targeted <sup>225</sup>Ac Alpha Particle Radioimmunotherapy Open
Figure S10: Tumor volumes, overall survival, and body weights for the saline and fractionated dose (0.125 µCi x 3) injections in 22Rv1 xenografts. Results show delayed tumor growth and improved survival without the significant toxicity fro…
View article: Figure S9 from Treatment of Prostate Cancer with CD46-targeted <sup>225</sup>Ac Alpha Particle Radioimmunotherapy
Figure S9 from Treatment of Prostate Cancer with CD46-targeted <sup>225</sup>Ac Alpha Particle Radioimmunotherapy Open
Figure S9: Histology evaluation of the healthy tissues for long-term (117 days) toxicity analysis. Hematoxylin and Eosin (H&E) staining of spleen, liver, lungs, heart, and bone samples show no toxicity at 0.25 µCi or 0.5 µCi doses of [225A…
View article: Figure S6 from Treatment of Prostate Cancer with CD46-targeted <sup>225</sup>Ac Alpha Particle Radioimmunotherapy
Figure S6 from Treatment of Prostate Cancer with CD46-targeted <sup>225</sup>Ac Alpha Particle Radioimmunotherapy Open
Figure S6: Number of H2AX-foci after the treatment of saline and [225Ac]DOTA-YS5 for 7 days and 14 days (n=3). t-test p value is indicated as * p<0.05.
View article: Supplementary Figure S14 from PET Imaging Using <sup>89</sup>Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer
Supplementary Figure S14 from PET Imaging Using <sup>89</sup>Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer Open
Supplementary Figure S14. Autoradiographic images and H&E staining images of PDX LTL-545 tumor sections from day 1 to day 4 post injection of 89Zr labeled nanocarriers.
View article: Supplementary Table S15 from PET Imaging Using <sup>89</sup>Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer
Supplementary Table S15 from PET Imaging Using <sup>89</sup>Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer Open
Supplementary Table S15. Organ biodistribution analysis data in %ID/g tissue for 89Zr labeled nanocarriers at 96 h in metastatic mice model with 22rv1 cell inoculated in kidney capsule tumors. (n = 4)
View article: Supplementary Figure S16 from PET Imaging Using <sup>89</sup>Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer
Supplementary Figure S16 from PET Imaging Using <sup>89</sup>Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer Open
Supplementary Figure S16. (a) White light images of LTL-610 tumors, and the respective (b) autoradiographic images of tumor sections on day 4 post injection of [89Zr]PEG-DFB4.
View article: Supplementary Figure S12 from PET Imaging Using <sup>89</sup>Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer
Supplementary Figure S12 from PET Imaging Using <sup>89</sup>Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer Open
Supplementary Figure S12. Autoradiographic images and H&E staining images of subcutaneous 22rv1 tumor sections from day 1 to day 4 post injection of 89Zr labeled nanocarriers. *Indicate the presence of necrosis.
View article: Supplementary Figure S9 from PET Imaging Using <sup>89</sup>Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer
Supplementary Figure S9 from PET Imaging Using <sup>89</sup>Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer Open
Supplementary Figure S9. Organ biodistribution presented in (left) %ID/g, and (right) %ID/organ for 89Zr labeled nanocarriers in nude mice bearing CT26 subcutaneous tumors at 96 h postinjection. (n = 5, mean ± SD)
View article: Supplementary Table S8 from PET Imaging Using <sup>89</sup>Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer
Supplementary Table S8 from PET Imaging Using <sup>89</sup>Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer Open
Supplementary Table S8. Organ biodistribution analysis data in %ID/g tissue for 89Zr labeled nanocarriers at 96 h in mice model bearing CT26 subcutaneous tumors. (n = 5)
View article: Supplementary Table S5 from PET Imaging Using <sup>89</sup>Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer
Supplementary Table S5 from PET Imaging Using <sup>89</sup>Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer Open
Supplementary Table S5. Region of interest analysis data reported as %ID/cc of the [89Zr]PEG-DFB1-TLZ3 on on different subcutaneous tumors from Day 1-4 post injection. (n = 4)
View article: Supplementary Table S9 from PET Imaging Using <sup>89</sup>Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer
Supplementary Table S9 from PET Imaging Using <sup>89</sup>Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer Open
Supplementary Table S9. Organ biodistribution analysis data in %ID/Organ tissue for 89Zr labeled nanocarriers at 96 h in mice model bearing CT26 subcutaneous tumors. (n = 5)
View article: Supplementary Figure S5 from PET Imaging Using <sup>89</sup>Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer
Supplementary Figure S5 from PET Imaging Using <sup>89</sup>Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer Open
Supplementary Figure S5. Coronal μPET/CT fusion and MIP images obtained at 24 h, 48 h, 72 h, and 96 h following administration of 150-170 μCi of 89Zr labeled nanocarriers in nude mice bearing CT26 subcutaneous tumors over left flanks.
View article: Supplementary Table S13 from PET Imaging Using <sup>89</sup>Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer
Supplementary Table S13 from PET Imaging Using <sup>89</sup>Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer Open
Supplementary Table S13. Organ biodistribution analysis data in %ID/Organ tissue for 89Zr labeled nanocarriers at 96 h in mice model bearing LTL-610 subcutaneous tumors. (n = 4)
View article: Supplementary Figure S1 from PET Imaging Using <sup>89</sup>Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer
Supplementary Figure S1 from PET Imaging Using <sup>89</sup>Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer Open
Supplementary Figure S1. (a) Zeta potential of the StarPEG conjugates PEG-DFB4 and PEG-DFB1-TLZ3 with an average surface charge of -4.04±0.21 mV and -1.41±0.22 mV, respectively (n = 3). (b) TEM images of PEG-DFB4 and PEG-DFB1-TLZ3 showing …
View article: Supplementary Figure S20 from PET Imaging Using <sup>89</sup>Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer
Supplementary Figure S20 from PET Imaging Using <sup>89</sup>Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer Open
Supplementary Figure S20. Organ biodistribution presented in (left) %ID/g, and (right) %ID/organ of [89Zr]PEG-DFB1-TLZ3 in nude mice inoculated with 22rv1 cells in the left kidney capsule at 96 h postinjection. (n = 4, mean ± SD)
View article: Supplementary Table S17 from PET Imaging Using <sup>89</sup>Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer
Supplementary Table S17 from PET Imaging Using <sup>89</sup>Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer Open
Supplementary Table S17. Organ biodistribution analysis data in %ID/g tissue for 89Zr labeled nanocarriers at 72 h in nude mice inoculated with 22rv1 cells via intracardiac injection. (n = 4)
View article: Supplementary Table S18 from PET Imaging Using <sup>89</sup>Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer
Supplementary Table S18 from PET Imaging Using <sup>89</sup>Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer Open
Supplementary Table S18. Organ biodistribution analysis data in %ID/Organ tissue for 89Zr labeled nanocarriers at 72 h in nude mice inoculated with 22rv1 cells via intracardiac injection. (n = 4)
View article: Supplementary Figure S22 from PET Imaging Using <sup>89</sup>Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer
Supplementary Figure S22 from PET Imaging Using <sup>89</sup>Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer Open
Supplementary Figure S22. BLI of all mice in the cohort inoculated with 22rv1-Luc cells in the left kidney capsule that demonstrate prominent signal of metastatic tumors at the neck and thigh region on the day of 89Zr labeled nanocarrier i…
View article: Supplementary Figure S2 from PET Imaging Using <sup>89</sup>Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer
Supplementary Figure S2 from PET Imaging Using <sup>89</sup>Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer Open
Supplementary Figure S2. Pilot PET/CT studies in prostate, pancreatic, and colorectal cancer models to measure the enhanced permeability retention effect using [89Zr]PEG-DFB1-TLZ3.
View article: Supplementary Figure S6 from PET Imaging Using <sup>89</sup>Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer
Supplementary Figure S6 from PET Imaging Using <sup>89</sup>Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer Open
Supplementary Figure S6. Coronal μPET/CT fusion and MIP images obtained at 24 h, 48 h, 72 h, and 96 h following administration of 150-170 μCi of 89Zr labeled nanocarriers in nude mice bearing LTL-545 patient derived xenograft (PDX) of tumo…
View article: Data from PET Imaging Using <sup>89</sup>Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer
Data from PET Imaging Using <sup>89</sup>Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer Open
The enhanced permeability and retention (EPR) effect controls passive nanodrug uptake in tumors and may provide a high tumor payload with prolonged retention for cancer treatment. However, EPR-mediated tumor uptake and distribution vary by…
View article: Supplementary Figure S21 from PET Imaging Using <sup>89</sup>Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer
Supplementary Figure S21 from PET Imaging Using <sup>89</sup>Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer Open
Supplementary Figure S21. Autoradiographic images and H&E staining images of metastatic tumor, and kedney sections from day 1 to day 4 post injection of [89Zr]PEG-DFB1-TLZ3 in nude mice inoculated with 22rv1 cells in the left kidney capsul…
View article: Supplementary Table S6 from PET Imaging Using <sup>89</sup>Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer
Supplementary Table S6 from PET Imaging Using <sup>89</sup>Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer Open
Supplementary Table S6. Organ biodistribution analysis data in %ID/g tissue for 89Zr labeled nanocarriers at 96 h in mice model bearing 22rv1 subcutaneous tumors. (n = 4)